VitaSpring Financial Statements From 2010 to 2025
| VSBC Stock | USD 1.00 0.00 0.00% |
Check VitaSpring Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VitaSpring Biomedical's main balance sheet or income statement drivers, such as , as well as many indicators such as . VitaSpring financial statements analysis is a perfect complement when working with VitaSpring Biomedical Valuation or Volatility modules.
VitaSpring |
VitaSpring Biomedical Co Company Return On Equity Analysis
VitaSpring Biomedical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current VitaSpring Biomedical Return On Equity | 0.84 |
Most of VitaSpring Biomedical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VitaSpring Biomedical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, VitaSpring Biomedical Co has a Return On Equity of 0.8416. This is 103.51% lower than that of the Healthcare sector and 102.31% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably lower than that of the firm.
VitaSpring Biomedical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining VitaSpring Biomedical's current stock value. Our valuation model uses many indicators to compare VitaSpring Biomedical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across VitaSpring Biomedical competition to find correlations between indicators driving VitaSpring Biomedical's intrinsic value. More Info.VitaSpring Biomedical Co is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.49 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for VitaSpring Biomedical Co is roughly 2.05 . Comparative valuation analysis is a catch-all model that can be used if you cannot value VitaSpring Biomedical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for VitaSpring Biomedical's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About VitaSpring Biomedical Financial Statements
VitaSpring Biomedical stakeholders use historical fundamental indicators, such as VitaSpring Biomedical's revenue or net income, to determine how well the company is positioned to perform in the future. Although VitaSpring Biomedical investors may analyze each financial statement separately, they are all interrelated. For example, changes in VitaSpring Biomedical's assets and liabilities are reflected in the revenues and expenses on VitaSpring Biomedical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in VitaSpring Biomedical Co. Please read more on our technical analysis and fundamental analysis pages.
The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. was incorporated in 2016 and is headquartered in Irvine, California. Vitaspring Biomedical operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in VitaSpring Pink Sheet
VitaSpring Biomedical financial ratios help investors to determine whether VitaSpring Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in VitaSpring with respect to the benefits of owning VitaSpring Biomedical security.